Akcea Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch AKCA and buy or sell other stocks, ETFs, and their options commission-free!About AKCA
Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology.
CEODamien McDevitt, PhD
CEODamien McDevitt, PhD
Employees—
Employees—
HeadquartersBoston, Massachusetts
HeadquartersBoston, Massachusetts
Founded2014
Founded2014
Employees—
Employees—
AKCA Key Statistics
Market cap1.85B
Market cap1.85B
Price-Earnings ratio-46.08
Price-Earnings ratio-46.08
Dividend yield—
Dividend yield—
Average volume476.70K
Average volume476.70K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$21.71
52 Week high$21.71
52 Week low$8.00
52 Week low$8.00
Stock Snapshot
With a market cap of 1.85B, Akcea Therapeutics(AKCA) trades at $18.17. The stock has a price-to-earnings ratio of -46.08.
Akcea Therapeutics(AKCA) stock opened on 2025-11-06 at —. The price climbed to — and dipped to —.
The Akcea Therapeutics(AKCA)'s current trading volume is 0, compared to an average daily volume of 476.7K.
During the past year, Akcea Therapeutics(AKCA) stock moved between $8.00 at its lowest and $21.71 at its peak.
During the past year, Akcea Therapeutics(AKCA) stock moved between $8.00 at its lowest and $21.71 at its peak.
People also own
Based on the portfolios of people who own AKCA. This list is generated using Robinhood data, and it’s not a recommendation.